CanSino Biologics (HKSE:06185) Debt-to-EBITDA : -3.31 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CanSino Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$1,037.4 Mil. CanSino Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$1,263.0 Mil. CanSino Biologics's annualized EBITDA for the quarter that ended in Mar. 2024 was HK$-696.1 Mil. CanSino Biologics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -3.30.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CanSino Biologics's Debt-to-EBITDA or its related term are showing as below:

HKSE:06185' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.85 Med: -1.42 Max: 0.67
Current: -1.12

During the past 8 years, the highest Debt-to-EBITDA Ratio of CanSino Biologics was 0.67. The lowest was -2.85. And the median was -1.42.

HKSE:06185's Debt-to-EBITDA is ranked worse than
100% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs HKSE:06185: -1.12

CanSino Biologics Debt-to-EBITDA Historical Data

The historical data trend for CanSino Biologics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Debt-to-EBITDA Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-1.24

-0.39

0.67

-2.85

-1.64

CanSino Biologics Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial													-	-0.58	-3.17	-1.34	-3.31

Competitive Comparison of CanSino Biologics's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CanSino Biologics's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's Debt-to-EBITDA falls into.

CanSino Biologics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CanSino Biologics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1596.368	+	1357.208)	/	-1800.017
	=	-1.64

CanSino Biologics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1037.445	+	1263.03)	/	-696.144
	=	-3.30

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

CanSino Biologics (HKSE:06185) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

CanSino Biologics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics (HKSE:06185) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

CASBF:USA CJH:Germany 688185:China

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

CanSino Biologics (HKSE:06185) Headlines

No Headlines